Johnson & Johnson (JNJ) Stock Analysis
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $228.92, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Weak growth.
Johnson & Johnson develops, manufactures and sells healthcare products through two segments: Innovative Medicine (prescription therapies across oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular/metabolism) and MedTech... Read more
Hold if already holding. Not a fresh buy at $228.92, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 5.4/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 57d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and news legal. Suitability: moderate.
About Johnson & Johnson
Johnson & Johnson generated approximately $88.8 billion of fiscal 2025 sales across two segments, Innovative Medicine and MedTech, with 43% of revenue sourced outside the United States (23% Europe, 15% Asia-Pacific and Africa, 5% Western Hemisphere ex-US). The DARZALEX franchise alone accounted for 15.0% of total revenues, STELARA contributed 6.5% and TREMFYA delivered 5.5%, anchoring an oncology, immunology and neuroscience-led therapeutic mix supported by 138,200 full-time-equivalent positions worldwide.
The Innovative Medicine segment distributes prescription medicines directly to retailers, wholesalers, distributors, hospitals and healthcare professionals, with concentrated revenue in CAR-T therapy CARVYKTI, daratumumab franchises DARZALEX and DARZALEX FASPRO, prostate-cancer agent ERLEADA, bispecifics TALVEY and TECVAYLI, IL-23 inhibitor TREMFYA, and oral anticoagulant XARELTO co-marketed with Bayer. The MedTech segment sells through hospitals, surgical centers and eye-care professionals, spanning electrophysiology, the Abiomed mechanical circulatory support portfolio, the Shockwave intravascular lithotripsy business, orthopaedics, surgery (including Mentor breast aesthetics) and the ACUVUE contact-lens and TECNIS intraocular-lens vision portfolios. Manufacturing runs through 63 facilities sourcing from thousands of suppliers, with third-party manufacturers producing certain raw materials, component parts and finished products. New products launched within the past five years contributed 25% of 2025 sales, and in October 2025 the company announced its intention to separate the Orthopaedics business, targeting completion within 18 to 24 months after the initial announcement.
Show full overview
The patent-cliff and IRA-pricing lens dominates the forward setup. STELARA, the second-largest product at 6.5% of revenue, faces ongoing global biosimilar launches the filing expects will continue to weigh on STELARA sales, while DARZALEX compound patents expire in the United States in 2029 with royalties to Genmab A/S of $2.4 billion paid in fiscal 2025. XARELTO and STELARA appear on the first CMS Selected Drug list with Medicare Part D pricing beginning in 2026, and in January 2026 CMS added ERLEADA to the 2028 list, pending Janssen's December 2025 U.S. Supreme Court petition challenging the IRA program. Talc litigation involving JOHNSON'S Baby Powder remains an additional overhang where the company self-insures via a captive.
See also: Healthcare · Drug Manufacturers - General
From Johnson & Johnson's most recent 10-K filing, extracted May 16, 2026.
Recent Developments — Johnson & Johnson
Latest news
- ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies — benzinga May 19, 2026 positive
- Supreme Court Hands Major Blow To Big Pharma's Fight Against Biden-Era Medicare Drug Pricing Law — benzinga May 19, 2026 negative
- 'Drug Companies Spurned by Supreme Court on Price Negotiation Law' - Bloomberg News — benzinga May 18, 2026 negative
- Congressman A Big Fan Of Dividend Reinvestments: Here's His Core Blue Chip Stocks — benzinga May 15, 2026 positive
- One Blue-Chip Stock Is Up 11% While the S&P 500 Struggles — benzinga May 15, 2026 neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $228.92, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $227.49 (-0.6%), stop $221.18 (−3.5%), A.R:R -0.1:1. Score 5.4/10, moderate confidence.
Take-profit target: $227.49 (-0.6% upside). Target $227.49 (-0.6%), stop $221.18 (−3.5%), A.R:R -0.1:1. Stop-loss: $221.18.
Analyst target reached - limited upside remaining; Weak growth.
Johnson & Johnson trades at a P/E of 26.5 (forward 18.0). TrendMatrix value score: 4.7/10. Verdict: Hold.
32 analysts cover JNJ with a consensus score of 3.8/5. Average price target: $253.
What does Johnson & Johnson do?Johnson & Johnson develops, manufactures and sells healthcare products through two segments: Innovative Medicine...
Johnson & Johnson develops, manufactures and sells healthcare products through two segments: Innovative Medicine (prescription therapies across oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular/metabolism) and MedTech (cardiovascular, orthopaedics, surgery and vision products). The company sells medicines to retailers, wholesalers, distributors, hospitals and healthcare professionals, and distributes MedTech products to hospitals, surgical centers and eye care professionals worldwide. In fiscal 2025, 43% of sales occurred outside the United Stat